Because TKIs, such as gefitinib and erlotinib, significantly improve the clinical outcome of EGFR‐mutant lung cancers, we also analyzed cachexia risk in patients with EGFR mutation by treatment with anti‐EGFR TKIs. This evidence concerns the gene EGFR and lung cancer.